title: [Experimental study for the targeting therapy of mouse lung carcinoma treated by anti-hnRNPB1 monoclonal antibody with 131I].
abstract: OBJECTIVE
  To evaluate the targeted therapeutic efficiencies of 131I-anti hnRNPB1 MAb (heterogeneous nuclear ribonucleoproteinB1, monoclonal antibody with 131I) and anti-hnRNP B1 MAb on the mice with implanted Lewis lung carcinoma. Methods Anti hnRNPB1 MAb was combined with 131I by routine chloramines-T method. The Lewis lung cancer cells were implanted subcutaneously into 30 C57BL/6 mice. After 7 d, the mice were divided into five groups. The mice in each group were injected with antibody or other reagent by tail vein respectively. For group I, the 131I-anti hnRNPB1 MAb 11.1 MBq single dose was administered. For group II, the 131I-anti hnRNPB1 MAb 11.1 MBq double doses (interval 3 d) were given. And the Na(131)I 11.1 MBq dosage was used to treat group III. For group IV, only anti-hnRNPB1 MAb 50 microg was conducted for mice. Group V was used as control. The toxic response was observed every day, and the size of tumor was measured weekly, and then the mice were killed four weeks after treatment. The tumor was resected and weighed. The inhibited rate of tumor growth was calculated and tumor tissue was pathologically detected.
  
  
  RESULTS
  After treatment the average tumor volumes of group I, II, III, IV, V were (3869 +/- 192) mm3, (1987 +/- 149) mm3, (6922 +/- 532) mm3, (6962 +/- 509) mm3, (6957 +/- 521) mm3 respectively. The average tumor volumes in I, II group were significantly smaller than those in V group (P < 0.05), also the average tumor volume in group II was significantly smaller than that in I group (P < 0.05). The average tumor volume showed no significant difference in III and IV group compared to the control groups. The inhibition rates of tumor growth in II and I group were 67.17% and 39.03% respectively, obviously higher than those in III (1.36%) and IV group (0.9%) (P < 0.05). The inhibition rates of tumor growth between II and I group also showed significant difference (P < 0.05).
  
  
  CONCLUSIONS
  It is showed that the Lewis lung cancer on mice can be inhibited by 131I-hnRNPB1 MAb and the inhibition rate of tumor growth is dose-response relationship.
authors.affiliation: Department of Respiratory Diseases and the State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
authors.forename: Ming-yong
authors.initials: MY
authors.lastname: Chen
authors.forename: Wei-min
authors.initials: WM
authors.lastname: Li
authors.forename: Dan
authors.initials: D
authors.lastname: Xu
authors.forename: Wen-bin
authors.initials: WB
authors.lastname: Chen
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018827:Carcinoma, Lewis Lung / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D034481:Heterogeneous-Nuclear Ribonucleoprotein Group A-B / Q000037:antagonists & inhibitors* / Q000276:immunology; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation
chemical_list: D000911:Antibodies, Monoclonal; D034481:Heterogeneous-Nuclear Ribonucleoprotein Group A-B; D007457:Iodine Radioisotopes; C439768:hnRNP A2